Sept. 30, 2022 Price forecast | 2 weeks: -2.94% | 1 month: -5.57% | 3 months: 8.16%

TCDA stock forecast

Our latest prediction for Tricida Inc's stock price was made on the Sept. 30, 2022 when the stock price was at 10.48$.

In the short term (2weeks), TCDA's stock price should underperform the market by -2.94%. During that period the price should oscillate between -13.51% and +6.66%.

In the medium term (3months), TCDA's stock price should outperform the market by 8.16%. During that period the price should oscillate between -30.94% and +35.13%.

Create a solid portfolio with TCDA

Add TCDA to your portfolio and optimize it!

About Tricida Inc

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -2.71$ per share.

The book value per share is 5.20$

Tricida Inc website

Three months stock forecastSept. 30, 2022


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -135M - -151M -2.71 - - 55M 5.20 - - -